FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 324:160-168 January 17, 1991 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy. Acceptance of this recommendation is controversial, since many women who would not have a recurrence would be treated. METHODS. Using a decision-analysis model, we studied the cost effectiveness of chemotherapy in cohorts of 45-year-old and 60-year-old women with node-negative breast cancer by calculating life expectancy as adjusted for quality of life. The analysis evaluated different scenarios of the benefit of therapy: improved disease-free survival for five years, with a lesser effect on overall survival (base line); a lifelong benefit from chemotherapy; and a benefit in disease-free survival with no change in overall survival by year 10. The base-line analysis assumed a 30 percent reduction in the relative risk of recurrence for five years after treatment. RESULTS. For the 45-year-old woman, the base-line analysis found an average lifetime benefit from chemotherapy of 5.1 quality-months at a cost of $15,400 per quality-year. The 60-year-old women gained 4.0 quality-months at a cost of $18,800 per quality-year. Under the more and less optimistic scenarios, the benefit of chemotherapy varied from 1.4 to 14.0 quality-months for both groups. CONCLUSIONS. Chemotherapy substantially increases the quality-adjusted life expectancy of an average woman at a cost comparable to that of other widely accepted therapies. This benefit decreases markedly if the changes in long-term survival are less than in disease-free survival. Given its uncertain duration, the benefit may be too small for many women to choose chemotherapy. Selective use of chemotherapy to maximize the benefit to individual patients may be possible with refinements in risk stratification and explicit assessment of the patients' risk preferences.

Source Information

Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond.

This article has been cited by other articles:

• Wolowacz, S. E., Cameron, D. A., Tate, H. C., Bagust, A. (2008). Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis. JCO 26: 925-933 [Abstract] [Full Text]  
• Kurian, A. W., Thompson, R. N., Gaw, A. F., Arai, S., Ortiz, R., Garber, A. M. (2007). A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast Cancer. JCO 25: 634-641 [Abstract] [Full Text]  
• Mandelblatt, J., Armetta, C., Yabroff, K. R., Liang, W., Lawrence, W. (2004). Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000. J Natl Cancer Inst Monogr 2004: 8-44 [Abstract] [Full Text]  
• Armstrong, K., Schwartz, J. S., Randall, T., Rubin, S. C., Weber, B. (2004). Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis. JCO 22: 1045-1054 [Abstract] [Full Text]  
• Elkin, E. B., Weinstein, M. C., Winer, E. P., Kuntz, K. M., Schnitt, S. J., Weeks, J. C. (2004). HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis. JCO 22: 854-863 [Abstract] [Full Text]  
• Lee, J. H., Glick, H. A., Hayman, J. A., Solin, L. J. (2002). Decision-Analytic Model and Cost-Effectiveness Evaluation of Postmastectomy Radiation Therapy in High-Risk Premenopausal Breast Cancer Patients. JCO 20: 2713-2725 [Abstract] [Full Text]  
• Love, R. R., Duc, N. B., Allred, D. C., Binh, N. C., Dinh, N. V., Kha, N. N., Thuan, T. V., Mohsin, S. K., Roanh, L. D., Khang, H. X., Tran, T. L., Quy, T. T., Thuy, N. V., The, P. N., Cau, T. T., Tung, N. D., Huong, D. T., Quang, L. M., Hien, N. N., Thuong, L., Shen, T.-z., Xin, Y., Zhang, Q., Havighurst, T. C., Yang, Y. F., Hillner, B. E., DeMets, D. L. (2002). Oophorectomy and Tamoxifen Adjuvant Therapy in Premenopausal Vietnamese and Chinese Women With Operable Breast Cancer. JCO 20: 2559-2566 [Abstract] [Full Text]  
• Esnaola, N. F., Lazarides, S. N., Mentzer, S. J., Kuntz, K. M. (2002). Outcomes and Cost-Effectiveness of Alternative Staging Strategies for Non-Small-Cell Lung Cancer. JCO 20: 263-273 [Abstract] [Full Text]  
• Jansen, S. J. T., Kievit, J., Nooij, M. A., Stiggelbout, A. M. (2001). Stability of Patients' Preferences for Chemotherapy: The Impact of Experience. Med Decis Making 21: 295-306 [Abstract]  
• Earle, C. C., Chapman, R. H., Baker, C. S., Bell, C. M., Stone, P. W., Sandberg, E. A., Neumann, P. J. (2000). Systematic Overview of Cost-Utility Assessments in Oncology. JCO 18: 3302-3317 [Abstract] [Full Text]  
• Schrag, D., Kuntz, K. M., Garber, J. E., Weeks, J. C. (2000). Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and BRCA1 or BRCA2 Mutations. JAMA 283: 617-624 [Abstract] [Full Text]  
• Holland, R. R., Ellis, C. A., Geller, B. M., Plante, D. A., Secker-Walker, R. H. (1999). Life Expectancy Estimation with Breast Cancer: Bias of the Declining Exponential Function and an Alternative to Its Use. Med Decis Making 19: 385-393 [Abstract]  
• Hrung, J. M., Langlotz, C. P., Orel, S. G., Fox, K. R., Schnall, M. D., Schwartz, J. S. (1999). Cost-effectiveness of MR Imaging and Core-Needle Biopsy in the Preoperative Work-up of Suspicious Breast Lesions. Radiology 213: 39-49 [Abstract] [Full Text]  
• Ng, A. K., Weeks, J. C., Mauch, P. M., Kuntz, K. M. (1999). Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis. JCO 17: 241-241 [Abstract] [Full Text]  
• Wright, J. C., Weinstein, M. C. (1998). Gains in Life Expectancy from Medical Interventions -- Standardizing Data on Outcomes. NEJM 339: 380-386 [Abstract] [Full Text]  
• Schrag, D., Kuntz, K. M., Garber, J. E., Weeks, J. C. (1997). Decision Analysis -- Effects of Prophylactic Mastectomy and Oophorectomy on Life Expectancy among Women with BRCA1 or BRCA2 Mutations. NEJM 336: 1465-1471 [Abstract] [Full Text]  
• Dalgleish, A G (1995). Chemotherapy for solid tumours. BMJ 310: 1328c-1329 [Full Text]  
• Retchin, S. M., Hillner, B. E. (1994). The Costs and Benefits of a Screening Program to Detect Dementia in Older Drivers. Med Decis Making 14: 315-324 [Abstract]  
• Richardson, G. E., Venzon, D. J., Phelps, R., Edison, M., Brown, M., Frame, J. N., Ihde, D. C., Johnson, B. E. (1993). Application of an Algorithm for Staging Small-cell Lung Cancer Can Save One Third of the Initial Evaluation Costs. Arch Intern Med 153: 329-337 [Abstract]  
• Levine, M. N., Gafni, A., Markham, B., MacFarlane, D. (1992). A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer. ANN INTERN MED 117: 53-58 [Abstract]  
• Mandelblatt, J. S., Wheat, M. E., Monane, M., Moshief, R. D., Hollenberg, J. P., Tang, J. (1992). Breast Cancer Screening for Elderly Women with and without Comorbid Conditions: A Decision Analysis Model. ANN INTERN MED 116: 722-730 [Abstract]  
• Hillner, B. E., Smith, T. J., Desch, C. E. (1992). Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer: Estimates Using Decision Analysis While Awaiting Clinical Trial Results. JAMA 267: 2055-2061 [Abstract]